CinRx Appoints Rez Halse, PhD, as President to Lead Its Portfolio of Clinical-Stage Development Companies and Accelerate Growth

Audio By Carbonatix

CINCINNATI--(BUSINESS WIRE)--Feb 10, 2026--

CinRx Pharma, a multi-asset clinical development organization, today announced the appointment of Rez Halse, PhD, as President. Dr. Halse brings more than 25 years of leadership in the pharmaceutical and biotech sectors, specializing in therapeutic discovery, translational development, business development, licensing, and venture capital.

“Rez’s extensive experience identifying breakthrough science of early-stage development candidates along with his investment strategy leadership in growth-phase companies, creates a powerful combination of skills that will propel CinRx forward into its next chapter,” said Jon Isaacsohn, MD, founder and CEO of CinRx. "I look forward to partnering closely with Rez as we expand our portfolio by identifying promising therapeutic candidates and guiding them efficiently through clinical development.”

Dr. Halse has built a strong foundation of clinical, financial, and strategic expertise throughout his career, including leading business development and licensing activities at Merck, serving as President of MRL Ventures Fund and RAven at RA Capital, sitting on more than twenty company boards, and driving the development of early-stage biotech companies in oncology, immunology, infectious disease, neurology, genetic diseases, and metabolic disorders. He holds a PhD in cell biology from Newcastle University and has published numerous articles in prestigious peer-reviewed journals, focusing on drug discovery and diabetes.

“CinRx has assembled an exceptional drug development team and operates a highly capital-efficient hub-and-spoke model for advancing promising therapeutic candidates to significant clinical inflections. This operational model is particularly well suited to the current biotech environment and, importantly, is scalable,” explained Rez Halse. “Drawing on the deep scientific, clinical and operational expertise of CinRx’s core team and network, we are eager to source new programs and expand our portfolio of clinical-stage companies.”

About CinRx Pharma

CinRx Pharma is a hub-and-spoke, multi-asset clinical development organization advancing a diverse portfolio of high-impact medicines. Benefiting from a strategic partnership with a leading CRO, deep access to capital, and insights from thousands of development programs, CinRx identifies, funds and advances promising drugs through clinical development. CinRx seeks to engage areas of high unmet medical need and is agnostic to drug modality and therapeutic area. CinRx Pharma is headquartered in Cincinnati, Ohio.

For more information, please visit www.CinRx.com or follow the company on X and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260210428300/en/

CONTACT: Media Contact:

[email protected] Pharma Contact:

Jason Westerheide

Executive Director, Business Development

[email protected]

KEYWORD: OHIO UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE

SOURCE: CinRx Pharma

Copyright Business Wire 2026.

PUB: 02/10/2026 08:00 AM/DISC: 02/10/2026 08:03 AM

http://www.businesswire.com/news/home/20260210428300/en